

Now Approved: New Cancer Drugs in Spring 2025

Here are the latest new cancer drugs approved by the Food and Drug Administration.

March 10, 2025 By [Liz Highleyman](#)

Here are the latest new cancer drugs approved by the Food and Drug Administration:

- Aucatxyl (obecabtagene autoleucel), a new CAR-T therapy for acute lymphoblastic leukemia
- Bizengri (zenocutuzumab), a bispecific antibody for lung cancer and pancreatic cancer
- Datroway (datopotamab deruxtecan), an antibody-drug conjugate for HER2-negative metastatic breast cancer
- Enhertu (fam-trastuzumab deruxtecan), an antibody-drug conjugate for HER2-ultralow metastatic breast cancer
- Ensacove (ensartinib), a targeted therapy for ALK-positive non-small-cell lung cancer
- Itovebi (inavolisib), a PI3K-pathway inhibitor for metastatic breast cancer
- Opdivo Qvantig, an injectable formulation of the PD-1 checkpoint inhibitor nivolumab
- Revuforj (revumenib), the first menin inhibitor for relapsed or refractory acute leukemia

- Unloxcyt (cosibelimab), a PD-L1 checkpoint inhibitor for cutaneous squamous cell carcinoma
- Vyloy (zolbetuximab), a claudin 18.2 monoclonal antibody, for HER2-negative stomach cancer
- Ziihera (zanidatamab), a bispecific antibody for HER2-positive biliary tract cancer